company background image
TYRA

Tyra Biosciences NasdaqGS:TYRA Stock Report

Last Price

US$12.14

Market Cap

US$505.0m

7D

13.5%

1Y

n/a

Updated

16 Aug, 2022

Data

Company Financials +
TYRA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

TYRA Stock Overview

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer.

Tyra Biosciences Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Tyra Biosciences
Historical stock prices
Current Share PriceUS$12.14
52 Week HighUS$31.36
52 Week LowUS$4.93
Beta0
1 Month Change25.80%
3 Month Change48.41%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-53.31%

Recent News & Updates

Aug 04

Tyra Biosciences GAAP EPS of -$0.36

Tyra Biosciences press release (NASDAQ:TYRA): Q2 GAAP EPS of -$0.36. As of June 30, 2022, TYRA had cash and cash equivalents of $275.1 million.

Jul 21
Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Shareholder Returns

TYRAUS BiotechsUS Market
7D13.5%1.4%3.6%
1Yn/a-19.6%-9.6%

Return vs Industry: Insufficient data to determine how TYRA performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how TYRA performed against the US Market.

Price Volatility

Is TYRA's price volatile compared to industry and market?
TYRA volatility
TYRA Average Weekly Movement16.7%
Biotechs Industry Average Movement12.6%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: TYRA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: TYRA's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201825Todd Harrishttps://www.tyra.bio

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers.

Tyra Biosciences Fundamentals Summary

How do Tyra Biosciences's earnings and revenue compare to its market cap?
TYRA fundamental statistics
Market CapUS$505.04m
Earnings (TTM)-US$46.49m
Revenue (TTM)n/a

0.0x

P/S Ratio

-10.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TYRA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$46.49m
Earnings-US$46.49m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.12
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did TYRA perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is TYRA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TYRA?

Other financial metrics that can be useful for relative valuation.

TYRA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-5x
PEG Ration/a

Price to Book Ratio vs Peers

How does TYRA's PB Ratio compare to its peers?

TYRA PB Ratio vs Peers
The above table shows the PB ratio for TYRA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average3.2x
BLUE bluebird bio
2.8x15.0%US$507.5m
ARCT Arcturus Therapeutics Holdings
3.2x71.0%US$543.2m
VXRT Vaxart
3.7x37.7%US$526.3m
MGTX MeiraGTx Holdings
3.3x47.8%US$470.4m
TYRA Tyra Biosciences
1.8x-24.8%US$505.0m

Price-To-Book vs Peers: TYRA is good value based on its Price-To-Book Ratio (1.8x) compared to the peer average (3.2x).


Price to Earnings Ratio vs Industry

How does TYRA's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: TYRA is good value based on its Price-To-Book Ratio (1.8x) compared to the US Biotechs industry average (2x)


Price to Book Ratio vs Fair Ratio

What is TYRA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TYRA PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate TYRA's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of TYRA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TYRA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TYRA's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Tyra Biosciences forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-24.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TYRA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TYRA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TYRA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TYRA is forecast to have no revenue next year.

High Growth Revenue: TYRA is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if TYRA's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Tyra Biosciences performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-195.3%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: TYRA is currently unprofitable.

Growing Profit Margin: TYRA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if TYRA's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare TYRA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TYRA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).


Return on Equity

High ROE: TYRA has a negative Return on Equity (-16.67%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Tyra Biosciences's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: TYRA's short term assets ($277.3M) exceed its short term liabilities ($5.5M).

Long Term Liabilities: TYRA's short term assets ($277.3M) exceed its long term liabilities ($2.8M).


Debt to Equity History and Analysis

Debt Level: TYRA is debt free.

Reducing Debt: TYRA has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TYRA has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: TYRA has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 78.1% each year.


Discover healthy companies

Dividend

What is Tyra Biosciences's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate TYRA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TYRA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TYRA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TYRA's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as TYRA has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Todd Harris (43 yo)

3.75yrs

Tenure

US$6,377,563

Compensation

Dr. Todd Harris, Ph D., serves as President, Chief Executive Officer and Secretary at Tyra Biosciences, Inc. since November, 2018 and serves as its Treasurer since February 2019. Dr. Harris serves as a Dir...


CEO Compensation Analysis

Compensation vs Market: Todd's total compensation ($USD6.38M) is above average for companies of similar size in the US market ($USD2.53M).

Compensation vs Earnings: Todd's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: TYRA's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

Experienced Board: TYRA's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: TYRA only recently listed within the past 12 months.


Top Shareholders

Company Information

Tyra Biosciences, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Tyra Biosciences, Inc.
  • Ticker: TYRA
  • Exchange: NasdaqGS
  • Founded: 2018
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$505.035m
  • Shares outstanding: 41.60m
  • Website: https://www.tyra.bio

Number of Employees


Location

  • Tyra Biosciences, Inc.
  • 2656 State Street
  • Carlsbad
  • California
  • 92008
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/16 00:00
End of Day Share Price2022/08/16 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.